Noordman BJ, et al. - Researchers assessed issues impacting patients’ preferences and trade-offs patients are willing to make in choosing between surgery and active surveillance for treatment after neoadjuvant chemoradiotherapy for esophageal cancer. They conducted a prospective discrete-choice experiment in which patients with esophageal cancer completed questionnaires 4–6 weeks after neoadjuvant chemoradiotherapy (nCRT) and before surgery. Findings revealed that patients are willing to trade off substantial 5-year survival to reduce the risk that esophagectomy is necessary.